A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699
Status:
Completed
Trial end date:
2019-11-13
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the
safety, tolerability, and pharmacokinetics (PK) of YG1699 following single and multiple
ascending oral dose administration.